Report #2827336

Received Feb 20, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 48 yrs
State: NY
Recovered: Unknown
Vaccinated: Aug 22, 2024
Onset: Aug 22, 2024
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	—	IM

Symptoms (2)

ErythemaRash

Symptom narrative

Second Dose of HEPLISAV-B Not Received; Rash; Red Skin; Initial report received on 05-Feb-2025. A reporter reported that a 48-year-old female (ethnicity not provided) received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and the patient developed red skin and rash. No medical history or concomitant medications were reported. On 22-Aug-2024, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot #, expiration date, NDC # 43528-002-01, site not available)] intramuscularly. At the time of reporting, more than a year after receiving the first dose, the patient presented to receive the second dose, but the site would not administer it. No additional information was reported. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.